Pliant Therapeutics ROCE 2024

Pliant Therapeutics Aktienanalyse

What does Pliant Therapeutics do?

Pliant Therapeutics Inc is a biopharmaceutical company located in South San Francisco, California. The company was founded in 2016 by a group of scientists specializing in the discovery of therapeutics for the treatment of fibrosis and cancer. The history of Pliant Therapeutics Inc begins with the discovery of proteins involved in the development of fibrosis. These proteins, known as integrins, play a key role in tissue repair and regeneration. However, when they are overactive, they can lead to an overproduction of connective tissue, resulting in fibrosis. Pliant Therapeutics Inc aims to develop innovative therapeutics for the treatment of fibrosis and cancer. The company utilizes an innovative business model based on the discovery and development of novel therapeutics targeting the regulation of integrins. The company specializes in various areas. One important focus is the research of therapeutics for the treatment of lung diseases such as idiopathic pulmonary fibrosis (IPF) and asthma. Pliant Therapeutics Inc focuses on the discovery of drugs that inhibit the fibrosis process and improve lung function. Another focus of Pliant Therapeutics Inc is the development of therapeutics for the treatment of connective tissue disorders, such as scleroderma and systemic lupus erythematosus (SLE). The company has also launched a program for the development of therapeutics for the treatment of cancer. Pliant Therapeutics Inc focuses on the discovery of drugs that inhibit tumor growth and improve the effectiveness of cancer drugs. Pliant Therapeutics Inc has several products in the pipeline, including PT004 for the treatment of lung diseases and PT001 for the treatment of scleroderma. PT004 is an inhalable drug that aims to inhibit the fibrosis process in the lungs. It is currently in Phase 2 of clinical development and has the potential to improve lung function in patients with idiopathic pulmonary fibrosis (IPF) and severe asthma. PT001 is an orally administered drug that targets the treatment of scleroderma. The drug is currently in preclinical development and has the potential to inhibit the fibrosis process in various organs. Overall, Pliant Therapeutics Inc has the potential to play a leading role in the discovery and development of novel therapeutics for the treatment of fibrosis and cancer. The company is well-funded and has an experienced team of scientists and managers specializing in the development of innovative therapeutics. Pliant Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Pliant Therapeutics's Return on Capital Employed (ROCE)

Pliant Therapeutics's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Pliant Therapeutics's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Pliant Therapeutics's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Pliant Therapeutics’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Pliant Therapeutics Stock

What is the ROCE (Return on Capital Employed) of Pliant Therapeutics this year?

The ROCE of Pliant Therapeutics is -0.39 undefined this year.

How has the ROCE (Return on Capital Employed) of Pliant Therapeutics developed compared to the previous year?

The ROCE of Pliant Therapeutics has increased by -4.23% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Pliant Therapeutics?

A high Return on Capital Employed (ROCE) indicates that Pliant Therapeutics has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Pliant Therapeutics?

A low ROCE (Return on Capital Employed) can indicate that Pliant Therapeutics has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Pliant Therapeutics impact the company?

An increase in the ROCE of Pliant Therapeutics can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Pliant Therapeutics affect the company?

A decrease in ROCE of Pliant Therapeutics can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Pliant Therapeutics?

Some factors that can affect Pliant Therapeutics's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Pliant Therapeutics so important for investors?

The ROCE of Pliant Therapeutics is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Pliant Therapeutics take to improve the ROCE?

To improve the ROCE, Pliant Therapeutics can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Pliant Therapeutics pay?

Over the past 12 months, Pliant Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Pliant Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Pliant Therapeutics?

The current dividend yield of Pliant Therapeutics is .

When does Pliant Therapeutics pay dividends?

Pliant Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Pliant Therapeutics?

Pliant Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Pliant Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Pliant Therapeutics located?

Pliant Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Pliant Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Pliant Therapeutics from 5/31/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/31/2024.

When did Pliant Therapeutics pay the last dividend?

The last dividend was paid out on 5/31/2024.

What was the dividend of Pliant Therapeutics in the year 2023?

In the year 2023, Pliant Therapeutics distributed 0 USD as dividends.

In which currency does Pliant Therapeutics pay out the dividend?

The dividends of Pliant Therapeutics are distributed in USD.